For example, CDK4/6 inhibitors, such as palbociclib, abemaciclib, and ribociclib, are used clinically to treat oestrogen receptor‐positive (ER+) and human epidermal growth factor receptor 2‐negative (HER2−) breast cancer [98]. Here, CDK4 is linked to breast cancer.